Does South Korea Need A State-Owned Pharma To Stabilize Supply?
This article was originally published in PharmAsia News
South Korea repeatedly faced drug supply disruptions when dealing with the outbreak of bird flu and new influenza, and when pharma firms refused to produce inexpensive but essential medicines, or drugs for rare diseases, due to low profitability. A local research paper now says the country may need a state-run pharma to ensure stable future supplies of essential medicines.
You may also be interested in...
South Korea unveils measures to stabilize supply of essential drugs – including a list of the drugs to monitor, stockpile and manage – to deal with public health crises in time and guarantee treatment opportunities for the nation.
SHANGHAI - Thailand's recent clampdown on public healthcare spending means multinational drug makers will have to look for news ways to tap the country's drug market, according to IMS Health
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.